Effect of I31 Probiotic on Lactose Intolerance

Lactose Intolerance Clinical Trial

Official title:

Efficacy of Probiotic I31 on Symptomatic Improvement in Patients With Lactose Intolerance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04164394
• Other study ID #: HJM 0431/18-R
• Status: Completed
• Phase: N/A
• Start date: May 13, 2019
• Est. completion date: December 31, 2019

Study information

• Verified date: February 2020
• Source: Hospital Juarez de Mexico
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized study evaluates the usefulness of the I31 probiotic formula, against placebo, in the treatment of symptoms of lactose intolerance.

Description:

People with lactose intolerance are unable to fully digest the sugar (lactose) in milk. As a result, they may have diarrhea, abdominal pain, gas and bloating after eating or drinking dairy products. A deficiency of lactase — an enzyme produced in your small intestine — is usually responsible for lactose intolerance. Many people have low levels of lactase but are able to digest milk products without problems. In lactose intolerance, though, lactase deficiency leads to symptoms after eating dairy foods.

I31 is a probiotic formula composed of Pediococcus acidilactici strain CECT7483 and Lactobacillus plantarum strains CECT7484 and CECT7485, previously shown to improve intestinal sensitivity in patients with Irritable Bowel Syndrome (IBS). IBS is a functional intestinal disease in which recurrent abdominal pain is associated with defecation or a change in bowel habits, often accompanied by bloating. Given the overlap in symptoms between IBS and lactose intolerance, it is hypothesized that I31 formula could be beneficial for individuals with lactose intolerance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: December 31, 2019
• Est. primary completion date: December 10, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Subjects attending Hospital Juarez de Mexico with self-reported lactose intolerance, a minimum lactose intolerance symptom score of 6 points, 20ppm during the Lactose Hydrogen Breath Test (LHBT) and providing Informed Consent.

Exclusion Criteria:

• More than 10 ppm before ingestion of lactose in the Lactose Hydrogen Breath Test (LHBT). If such value was observed, the LHBT test was repeated on a 2nd day, and if >10ppm persisted, patient was excluded.

• BMI below 18 or above 40

• Subjects not accepting to maintain their dietary and physical activity pattern unchanged for the duration of the study

• Subjects with congenital lactase deficiency

• Pregnant or lactating women

• Significant gastrointestinal disease, such as inflammatory bowel disease, coeliac disease, chronic diarrhea or gastroparesis

• History of gastrointestinal surgery in the 6 months prior to inclusion

• History of intestinal perforation

• History of acute gastroenteritis, acute gastroenteritis or hospitalization in the 4 weeks prior to inclusion

• Substance abuse

• Untreated thyroid disorder

• Cancer

• Other severe diseases that in the doctor's opinion could interfere with the study

• Known allergy to any of the components in the treatments

Related Conditions & MeSH terms

• Lactose Intolerance

Intervention

Other:
• Placebo
Placebo treatment (maltodextrin), once daily (u.i.d)

Dietary Supplement:
• I31 Probiotic
I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)

Locations

Country	Name	City	State
Mexico	Hospital Juarez de Mexico	Mexico City	Cdmx

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Juarez de Mexico

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Symptoms Score	Total score of the "Symptoms Questionnaire for Lactose Malabsorption Screening" (Casellas et al. Dig Dis Sci 2009; 54:1059-65). Score ranges 0 to 50, where 50 represents maximum symptoms severity	3 hours (performed after 25 gr lactose challenge, at baseline and after 8 weeks of intervention)
Secondary	Abdominal Pain subscore	Abdominal pain Visual Analog Scale (VAS) subscore of the "Symptoms Questionnaire for Lactose Malabsorption Screening". Score ranges 0 to 10, where 10 represents maximum pain severity (Casellas et al. Dig Dis Sci 2009; 54:1059-65)	3 hours (performed after 25 gr lactose challenge, at baseline and after 8 weeks of intervention)
Secondary	Vomiting subscore	Vomiting Visual Analog Scale (VAS) subscore of the "Symptoms Questionnaire for Lactose Malabsorption Screening". Score ranges 0 to 10, where 10 represents maximum vomiting severity (Casellas et al. Dig Dis Sci 2009; 54:1059-65)	3 hours (performed after 25 gr lactose challenge, at baseline and after 8 weeks of intervention)
Secondary	Intestinal Sounds subscore	Intestinal Visual Analog Scale (VAS) sounds subscore of the "Symptoms Questionnaire for Lactose Malabsorption Screening". Score ranges 0 to 10, where 10 represents maximum intestinal sounds severity (Casellas et al. Dig Dis Sci 2009; 54:1059-65)	3 hours (performed after 25 gr lactose challenge, at baseline and after 8 weeks of intervention)
Secondary	Flatulence subscore	Flatulence Visual Analog Scale (VAS) subscore of the "Symptoms Questionnaire for Lactose Malabsorption Screening". Score ranges 0 to 10, where 10 represents maximum flatulence severity (Casellas et al. Dig Dis Sci 2009; 54:1059-65)	3 hours (performed after 25 gr lactose challenge, at baseline and after 8 weeks of intervention)
Secondary	Lactose Hydrogen Breath Test (LHBT)	LHBT test performed with 25 gr of lactose after an overnight fast. Measurements 10 minutes before lactose ingestion and 60, 120 and 180 minutes after lactose ingestion. CO2 (Carbon Dioxide) used as control. If more than 10ppm in the measurement before ingestion of lactose, and LHBT test was rescheduled and recommendations to avoid complex carbohydrates 24h before the test were repeated. Carbon dioxide (CO2) was measured and used to adjust breath sample for non-alveolar dilution of exhaled air.	3 hours (performed after 25 gr lactose challenge, at baseline and after 8 weeks of intervention)